BRAF and melanoma: V600E mutation is clinically relevant, because based on its presence, many patients receive targeted therapy, although paradoxically, BRAF V600E has been reported to be more frequent in benign (≈80%) than in dysplastic nevi (≈60%) or melanoma (≈40%-45%) [3, 4].